Komori
Revision of earnings forecasts4880CellSource Co.,Ltd.Pharmaceuticals

Notice Regarding Revisions to the Earnings Forecast

The standalone full-year forecast for the fiscal year ending October 2026 has been revised. Net sales have been revised upward by ¥47 million, operating income by ¥303 million and ordinary income by ¥286 million. Meanwhile, net income has been revised downward by ¥16 million due to the expected recognition of an extraordinary loss of ¥290 million associated with the relocation of the head office.

Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
303
million yen
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending October 2026 · Full yearPrevious forecast published 29 July 2026
Net Sales3,320→3,367million yen
+1.4%
Operating profit-221→82million yen
+137.1%
Ordinary income-210→76million yen
+136.2%
Profit attributable to owners of the parent-107→-124million yen
-15.9%
Net income per share-5.41→-6.26yen
-15.7%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

In addition to net sales, led by contract processing services, continuing to exceed the initial forecast, operating income and ordinary income are expected to exceed the initial forecast due to reduced selling, general and administrative expenses through business selection and concentration. Meanwhile, net income (loss) is expected to fall below the initial forecast because an extraordinary loss of ¥290 million is expected to be recognized following the decision to relocate the head office.

Details and amount of extraordinary loss

Expected recognition of an extraordinary loss of ¥290 million associated with the relocation of the head office

Consolidated / non-consolidatedNon-consolidated
Revised forecast
ItemDetails
Net Sales3,320 million yen → 3,367 million yen(1.4%)
Operating profit-221 million yen → 82 million yen(-%)
Ordinary income-210 million yen → 76 million yen(-%)
Profit attributable to owners of the parent-107 million yen → -124 million yen(-%)
Net income per share-5.41 yen → -6.26 yen(-%)
Fiscal Period CoveredFiscal year ending October 2026
Period CoveredFull year
Publication date of previous forecast29 July 2026
Reason for the revisionIn addition to net sales, led by contract processing services, continuing to exceed the initial forecast, operating income and ordinary income are expected to exceed the initial forecast due to reduced selling, general and administrative expenses through business selection and concentration. Meanwhile, net income (loss) is expected to fall below the initial forecast because an extraordinary loss of ¥290 million is expected to be recognized following the decision to relocate the head office.
Details and amount of extraordinary lossExpected recognition of an extraordinary loss of ¥290 million associated with the relocation of the head office
Consolidated / non-consolidatedNon-consolidated
Items this document does not state (2)
Previous-period resultsDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Operating income and ordinary income have been revised upward because net sales, led by contract processing services, have been exceeding the forecast, and selling, general and administrative expenses have been reduced through business selection and concentration. Meanwhile, net income has been revised downward because an extraordinary loss of ¥290 million is expected to be recognized following the decision to relocate the head office.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to the Earnings Forecast | CellSource Co.,Ltd. (4880) timely disclosure | Komori